je.st
news
Tag: merck
Merck Announces FDA Acceptance of New Drug Application for an Investigational Tablet Formulation of the Antifungal NOXAFIL (posaconazole)
2013-04-10 14:30:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION N.J. WHITEHOUSE STATION N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration (FDA). Language: English Contact HTML: MerckMedia:Pam Eisele, (908) 423-5042Robert Consalvo, (908) 423-6595orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
application
drug
acceptance
Merck to Present New Data on VICTRELIS (boceprevir) and Investigational Compounds MK-5172 and Vaniprevir for Chronic Hepatitis C Virus at The International Liver CongressTM / 2013 EASL Annual Meeting
2013-04-08 16:37:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Mercks investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting. The meeting will take place in Amsterdam from April 24-28, 2013. Language: English Contact HTML: MerckMedia:Caroline Lappetito, 267-305-7369Sarra Herzog, 908-423-6154orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
international
present
meeting
Merck to Hold First-Quarter 2013 Sales and Earnings Conference Call on May 1
2013-04-01 14:30:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2013 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Wednesday, May 1. During the call, Kenneth C. Frazier, chairman and chief executive officer; Peter N. Kellogg, executive vice president and chief financial officer; and Adam H. Schechter, president, Global Human Health, will provide an overview of Mercks financial performance for the quarter. Language: English Contact HTML: MerckMedia:Steven Cragle, 908-423-3461orKelley Dougherty, 908-423-4291orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck KGaA Stock Rating Reaffirmed by AlphaValue
2013-03-29 18:21:23| Biotech - Topix.net
's stock had its "sell" rating restated by analysts at AlphaValue in a research report issued to clients and investors on Friday.
Tags: rating
stock
merck
reaffirmed
Merck: FDA Reviewing Tablet to Eliminate Allergy
2013-03-28 17:38:48| Biotech - Topix.net
Drugmaker Merck & Co. said Wednesday that federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that gradually reduces allergy symptoms over time, rather than just temporarily relieving the sneezing and itching.
Tags: eliminate
reviewing
tablet
allergy
Sites : [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] next »